Associations - buparlisib (AN2025)

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
AKT1 amplification	Triple Negative Breast Cancer	AKT1 amplification	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
AKT1 E17K	Triple Negative Breast Cancer	AKT1 E17K	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib + AN2025 Sensitive: C3 – Early Trials ribociclib + AN2025 Sensitive : C3	ribociclib + AN2025 Sensitive: C3 – Early Trials ribociclib + AN2025 Sensitive : C3
TSC1 deletion	Urothelial Cancer	TSC1 deletion	Urothelial Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
SIRT6 underexpression	Colon Cancer	SIRT6 underexpression	Colon Cancer	AN2025 Resistant: C3 – Early Trials AN2025 Resistant : C3	AN2025 Resistant: C3 – Early Trials AN2025 Resistant : C3
FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck	FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
FANCA mutation + FGFR3 mutation	Squamous Cell Carcinoma of Head and Neck	FANCA mutation + FGFR3 mutation	Squamous Cell Carcinoma of Head and Neck	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
FANCD2 mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck	FANCD2 mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
PIK3CA mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
PTEN K237fs	Triple Negative Breast Cancer	PTEN K237fs	Triple Negative Breast Cancer	AN2025 Sensitive: C4 – Case Studies AN2025 Sensitive : C4	AN2025 Sensitive: C4 – Case Studies AN2025 Sensitive : C4
EGFR overexpression + HER-2 overexpression	Cholangiocarcinoma	EGFR overexpression + HER-2 overexpression	Cholangiocarcinoma	AN2025 + ASLAN001 Sensitive: D – Preclinical AN2025 + ASLAN001 Sensitive : D	AN2025 + ASLAN001 Sensitive: D – Preclinical AN2025 + ASLAN001 Sensitive : D
STK11 deletion	Non Small Cell Lung Cancer	STK11 deletion	Non Small Cell Lung Cancer	AN2025 + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AN2025 + nanoparticle albumin-bound rapamycin Sensitive : D	AN2025 + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AN2025 + nanoparticle albumin-bound rapamycin Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	AN2025 Sensitive: D – Preclinical AN2025 Sensitive : D	AN2025 Sensitive: D – Preclinical AN2025 Sensitive : D
MAP3K1 mutation	Estrogen Receptor Positive Breast Cancer	MAP3K1 mutation	Estrogen Receptor Positive Breast Cancer	AN2025 Sensitive: D – Preclinical AN2025 Sensitive : D	AN2025 Sensitive: D – Preclinical AN2025 Sensitive : D
TP53 mutation	Medulloblastoma	TP53 mutation	Medulloblastoma	AN2025 + panobinostat Sensitive: D – Preclinical AN2025 + panobinostat Sensitive : D	AN2025 + panobinostat Sensitive: D – Preclinical AN2025 + panobinostat Sensitive : D
TP53 mutation	Medulloblastoma	TP53 mutation	Medulloblastoma	AN2025 Resistant: D – Preclinical AN2025 Resistant : D	AN2025 Resistant: D – Preclinical AN2025 Resistant : D
TP53 mutation	Medulloblastoma	TP53 mutation	Medulloblastoma	AN2025 + sirolimus Sensitive: D – Preclinical AN2025 + sirolimus Sensitive : D	AN2025 + sirolimus Sensitive: D – Preclinical AN2025 + sirolimus Sensitive : D
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	trametinib + osimertinib + AN2025 Sensitive: D – Preclinical trametinib + osimertinib + AN2025 Sensitive : D	trametinib + osimertinib + AN2025 Sensitive: D – Preclinical trametinib + osimertinib + AN2025 Sensitive : D

buparlisib (AN2025)

Associations
(20)

Associations
(20)

buparlisib (AN2025)

Associations(20)

Associations(20)

Associations
(20)

Associations
(20)